Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
- Conditions
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT02417285
- Locations
- 🇳🇱
Local Institution - 201, Amsterdam, Netherlands
🇳🇱Local Institution - 202, Rotterdam, Netherlands
🇫🇷Local Institution - 105, Borddeaux Cedex, France
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 47
- Registration Number
- NCT02406742
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇦🇹University Hospital of Salzburg St Johanns Spital, Salzburg, Austria
🇺🇸The West Clinic, Memphis, Tennessee, United States
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 25
- Registration Number
- NCT02393157
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 55
- Registration Number
- NCT02391545
Lenalidomide and Obinutuzumab for Previously Untreated CLL
- Conditions
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- University of California, San Diego
- Registration Number
- NCT02371590
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
- Conditions
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02336048
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain
🇪🇸Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain
🇮🇹Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT02324257
- Locations
- 🇺🇸
Cedars Sinai Medical Center; Samuel-Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇪🇸START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇺🇸Stanford University, Palo Alto, California, United States
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02320487
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States
🇺🇸San Juan Oncology Associates, Farmington, New Mexico, United States
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 69
- Registration Number
- NCT02296918
- Locations
- 🇺🇸
Research Site, Columbus, Ohio, United States
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 3
- Registration Number
- NCT02292225
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.